Download full text PDF

A. Pereverzev, Candidate of Medical Sciences; В. Romanov, MD; Professor R. Alyautdin, MD; Professor N. Bunyatyan, PhD; A. Elapov Scientific Centre for Expert Evaluation of Medicinal Products of the Ministry of Health of Russia

To optimize prospective methods of evaluation of drugs interchangeability a patent research was conducted. The results of the patent research are presented in this article. The outcome of this exploration will help to optimize the process of comparative evaluation of the reference drug and generic (or biosimilar).

methods of evaluation

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

  1. Godman B., Wettermark B., Bishop I. et al. European payer initiatives to reduce prescribing costs through use of generics // GaBI J. – 2012; 1: 22–7
  2. Ministry of Health. Labour and Welfare of Japan. Policy Report: Promotion of the use of generic drugs; 2012. Available at:
  3. Andersson K., Bergstrom G., Petzold M. et al. Impact of a generic substitution reform on patients’ and society’s expenditure for pharmaceuticals // Health Policy. – 2007; 81: 376–84.
  4. Coombes R. GPs save 4. £400m in 2008 by increasing use of generic drugs // BMJ. – 2009; 338: b2044
  5. European Generic Medicines Association (EGA). Ega fact sheet on generic 5. medicines: generic medicines provide front-Line treatment for chronic illnesses & conditions. Available at:
  6. European Generic Medicines Association (EGA). Frequently fsked questions about generic medicines; 2007. Available at:
  7. Godman B., Shrank W., Wettermark B. et al. Use of genericsda critical cost containment measure for all healthcare professionals in Europe? // Pharmaceuticals. – 2010; 3: 2470–94.
  8. Sheppard A. Generic medicines: essential contributors to the long-term health of society. IMS Health. Available at: imshealth/Global/Content/Document/Market_Measurement_TL/Generic_Medicines_GA.pdf.
  9. Aljautdin R.N., Romanov B.K., Pereverzev A.P. i dr. Elektronnaja sistema vypisyvanija retseptov i bezopasnost' lekarstvennoj terapii // Vedomosti nauchnogo tsentra ekspertizy sredstv meditsinskogo primenenija. – 2014; 2: 30–4.
  10. Duerden M., Hughes D. Generic and therapeutic substitutions in the UK: are they a good thing? // Br. J. Clin. Pharmacol. – 2010; 70: 335–41.
  11. Ferner R., Lenney W., Marriott J. Controversy over generic substitution // BMJ. – 2010; 340: 3570.
  12. Holmes D., Becker J., Limacher M. et al. ACCF/AHA 2011 health policy statement on therapeutic interchange and substitution: a report of the American College of Cardiology Foundation Clinical Quality Committee // Circulation. – 2011; 124: 1290–310.
  13. Svodnyj otchet o provedenii otsenki regulirujuschego vozdejstvija (Tsit. po, data obraschenija – 12.01.2015).
  14. Federal'nyj Zakon №429-FZ ot 22.12.2014 «O vnesenii izmenenij v federal'nyj zakon «Ob obraschenii lekarstvennyh sredstv»» (Tsit. po sist. «Konsul'tant pljus», data obraschenija – 12.01.2015).
  15. Federal'nyj zakon ot 12.04.2010 №61-FZ (red. ot 22.10.2014) «Ob obraschenii lekarstvennyh sredstv» (Tsit. po sist. «Konsul'tant Pljus», data obraschenija – 12.01.2015).
  16. Multisource (generic) pharmaceutical products: guidelines on registration requirements to establish interchangeability. WHO Technical Report Series, No. 937, 2006 (Tsit. po, data obraschenija – 12.01.2015).
  17. Mei-Ling Chen. Harmonization of regulatory approaches for evaluating therapeutic equivalence and interchangeability of multisource drug products: workshop summary report // AAPS J. – 2011; 13 (4): 556–64.